AARD - Aardvark Therapeutics, Inc.
3.55
0.040 1.127%
Share volume: 225,109
Last Updated: 03-27-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.18%
PREVIOUS CLOSE
CHG
CHG%
$3.51
0.04
0.01%
View ratios
| Fiscal Date | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|
| Fiscal Quarter | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-14-2025 | 11-13-2025 | 03-23-2026 | |
| Total revenue | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | |||
| Operating expenses | 10.470 M | 17.703 M | 18.704 M | |
| Selling general and admin | 2.715 M | 3.966 M | 4.405 M | |
| Research and development | 7.755 M | 13.737 M | 14.299 M | |
| Total expenses | 10.470 M | 17.703 M | 18.704 M | |
| 69.08% | 5.65% | |||
| Operating income | -10.470 M | -17.703 M | -18.704 M | |
| Ebit | -10.485 M | -17.667 M | -18.723 M | |
| Pretax income | -9.310 M | -16.316 M | -17.598 M | |
| 75.25% | 7.86% | |||
| Income tax | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | |
| Net income | -9.310 M | -16.316 M | -17.598 M | |
| -75.25% | -7.86% |